How about DSCO ? It's drifting again, near a 52-week low. Priced like a company in mid-phase III trials, whereas in fact only CMC issues remain. Big pipeline too in areas with sparse competition. Defintiely getting near my target for a purchase.
"....on the biotech battle-field, you need some élan...."